Cognitive Function with PCSK9 Inhibitors: A 24-Month Follow-Up Observational Prospective Study in the Real World-MEMOGAL Study - American Journal of Cardiovascular Drugs
Source : https://link.springer.com/article/10.1007/s40256-023-00604-6
Introduction The cognitive safety of monoclonal antibody proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) has been established in clinical trials, but not yet in real-world observational studies. We assessed the...
Conclusion: We did not find effect of monoclonal antibody PCSK9i on neurocognitive function over 24 months of treatment, either in global MoCA score or different cognitive domains. An improvement in delayed recall memory was shown. The study showed no differences in the cognitive function between the prespecified subgroups, even among...
Share
Appropriateness of Dyslipidemia Management Strategies in Post-Acute Coronary Syndrome: A 2023 Update - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37623860/
It has been consistently demonstrated that circulating lipids and particularly low-density lipoprotein cholesterol (LDL-C) play a significant role in the development of coronary artery disease (CAD). Several trials have been...
Conclusions/Relevance: This review aims to discuss the possible lipid-lowering strategies in post-ACS and to identify those patients who might benefit most from more powerful treatments and up-to-date management.
Share
Causal relationship between PCSK9 inhibitor and autoimmune diseases: a drug target Mendelian randomization study - Arthritis Research & Therapy
Source : https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-023-03122-7
Background In addition to decreasing the level of cholesterol, proprotein convertase subtilis kexin 9 (PCSK9) inhibitor has pleiotropic effects, including immune regulation. However, the impact of PCSK9 on autoimmune diseases...
Conclusions: PCSK9 inhibitor significantly reduced the risk of SLE but increased the risk of asthma and CD. In contrast, HMGCR inhibitor may be a risk factor for RA, asthma, and CD.
Share
Strategies of improving adherence to lipid-lowering therapy in patients with atherosclerotic cardiovascular disease
Source : https://journals.lww.com/co-lipidology/abstract/9900/strategies_of_improving_adherence_to.45.aspx
agement in patients with ASCVD focusing on the provider, patient, and system level. Recent findings At a provider level, under-prescribing of statin intensity due most often to statin intolerance, clinical...
Summary: To improve cholesterol management in ASCVD patients will require an integrated approach targeting the provider, the patient and the system. There is a need for further education of clinicians on the importance of intensive LDL-C lowering in ASCVD patients and greater use of nonstatin LDL-C-lowering therapies for those patients on a...
Share
Targeting PCSK9 and Beyond for the Management of Low-Density Lipoprotein Cholesterol - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/37568484/
Reducing low-density lipoprotein cholesterol (LDL-C) levels is crucial to the prevention of atherosclerotic cardiovascular disease (ASCVD). However, many patients, especially those at very high ASCVD risk or with familial hypercholesterolemia...
Conclusions/Relevance: These strategies demonstrate significant LDL-C reductions and improved cardiovascular outcomes, offering potential for optimal LDL-C control and reduced ASCVD risk. By addressing the limitations of statin monotherapy, these approaches provide new management options for elevated LDL-C levels.
Share